News
-
-
COMMUNIQUÉ DE PRESSE
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. to showcase revolutionary antiviral drug NV-387 at LSX World Congress 2025 in Boston. Update on drug pipeline and platform technologies by Dr. Diwan -
-
-
COMMUNIQUÉ DE PRESSE
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
NanoViricides, Inc. reports NV-387 antiviral drug could reduce metastatic cancer resurgence caused by viral infections. NV-387 completed Phase I trial, advancing to Phase II -
-
